Biodexa expects 1-for-8 depositary share exchange

ADS holders will exchange eight existing ADSs for one new ADS, while the company's ordinary shares remain unchanged.

Rhea-AI Filing Summary

Biodexa Pharmaceuticals Plc (BDRX) announced an American Depositary Share ratio change expected to take effect on or about October 26, 2026: one ADS will represent 400 ordinary shares, compared with one ADS representing 50 ordinary shares under the prior ratio.

ADS holders must surrender existing ADSs for cancellation and exchange to receive one new ADS for every eight old ADSs. No fractional ADSs will be allocated; any aggregate fractions will be sold, with net proceeds distributed to the entitled ADS holders. JPMorgan Chase Bank, N.A., the depositary, will contact holders and arrange the exchange. The ordinary shares themselves will not be affected.

Key Figures

Prior ADS ratio: 1 ADS per 50 ordinary shares New ADS ratio: 1 ADS per 400 ordinary shares ADS exchange ratio: 1 new ADS for every 8 old ADSs +1 more

4 metrics

Prior ADS ratio 1 ADS per 50 ordinary shares Ratio before the change

New ADS ratio 1 ADS per 400 ordinary shares Ratio after the change

ADS exchange ratio 1 new ADS for every 8 old ADSs Mandatory exchange for ADS holders

Expected effective date On or about October 26, 2026 ADS ratio change

Key Terms

American Depositary Shares, ADS ratio, fractional ADSs

3 terms

American Depositary Shares financial

"American Depositary Shares (“ADSs”)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ADS ratio financial

"a ratio change of its American Depositary Shares"

The ads ratio measures the proportion of a company's revenue that comes from advertising activities compared to other sources. It helps investors understand how much of a company's income depends on advertising efforts, similar to how a restaurant's income might rely heavily on dine-in sales versus takeout. A higher ads ratio indicates a greater dependence on advertising-related revenue, which can signal potential risks or opportunities depending on market trends.

fractional ADSs financial

"No fractional ADSs will be allocated"

Fractional ADSs are portions of shares in a foreign company that are traded on a stock exchange through American Depositary Shares (ADSs). Instead of buying a full share, investors can purchase smaller parts, making it easier and more affordable to invest in companies from other countries. This allows more people to participate in international markets and diversify their investment portfolios.

Stock Split

1-for-8 reverse split · Effective October 26, 2026

Split Ratio 1-for-8 reverse split

Effective Date October 26, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is BDRX's new ADS ratio?

Biodexa's new ratio is one ADS representing 400 ordinary shares, compared with one ADS representing 50 ordinary shares under the prior ratio. Holders will exchange one new ADS for every eight old ADSs.

When is BDRX's ADS ratio change expected to take effect?

The ratio change is expected to take effect on or about October 26, 2026. JPMorgan Chase Bank, N.A., the depositary, will contact ADS holders and arrange the exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/08/2026 - 04:03 PM Accepted by SEC EDGAR 10/08/2026 - 04:03 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number 001-37652

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x      Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On October 8, 2026, Biodexa Pharmaceuticals PLC (the “Company”) announced a ratio change of its American Depositary Shares (“ADSs”) from one (1) ADS representing fifty (50) of its ordinary shares, to a new ratio of one (1) ADS representing four hundred (400) ordinary shares (the “Ratio Change”). The effective date of the Ratio Change is expected to be on or about October 26, 2026.

Pursuant to the Ratio Change, ADS holders will be required on a mandatory basis to surrender their ADSs for cancellation and exchange to receive one (1) new ADS (New CUSIP: 59564R864) for every eight (8) old ADSs (Old CUSIP: 59564R872). No fractional ADSs will be allocated. The aggregate fractions, if any, will be sold and the net proceeds will be distributed to the entitled ADS holder. The Company's Depositary, JPMorgan Chase Bank, N.A. will contact ADS holders and arrange for the exchange of their existing ADSs for new ADSs.

For ADS holders, the Ratio Change will have the same effect as a one-for-eight reverse ADS split. The ordinary shares of the Company will not be affected by this change.

The information in this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-209365) and Form F-3 (File No. 333-290554) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Biodexa Pharmaceuticals PLC
Date: October 8, 2026	By:	/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer